Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections

Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections

Abstract Background A challenge in the empiric treatment of complicated urinary tract infection (cUTI) is identifying the initial appropriate antibiotic therapy (IAAT), which is associated with reduced length of stay and mortality compared with initial inappropriate antibiotic therapy (IIAT). We eva...

Full description

Bibliographic Details
Main Authors: Teresa L Kauf, Vimalanand S. Prabhu, Goran Medic, Rebekah H. Borse, Benjamin Miller, Jennifer Gaultney, Shuvayu S. Sen, Anirban Basu
Format: Article
Language:English
Published: BMC 2017-04-01
Series:BMC Infectious Diseases
Subjects:
Cost-benefit analysis
Ceftolozane
Piperacillin
Tazobactam
Urinary tract infections
United States
Online Access:http://link.springer.com/article/10.1186/s12879-017-2408-7

Internet

http://link.springer.com/article/10.1186/s12879-017-2408-7

Similar Items